PL2315773T3 - Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy - Google Patents

Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy

Info

Publication number
PL2315773T3
PL2315773T3 PL09781052T PL09781052T PL2315773T3 PL 2315773 T3 PL2315773 T3 PL 2315773T3 PL 09781052 T PL09781052 T PL 09781052T PL 09781052 T PL09781052 T PL 09781052T PL 2315773 T3 PL2315773 T3 PL 2315773T3
Authority
PL
Poland
Prior art keywords
tubeculosis
polynucleotides
polypeptides
latent
compositions
Prior art date
Application number
PL09781052T
Other languages
English (en)
Inventor
James Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biologicals S.A.
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A., Glaxo Group Limited filed Critical Glaxosmithkline Biologicals S.A.
Publication of PL2315773T3 publication Critical patent/PL2315773T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL09781052T 2008-07-25 2009-07-24 Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy PL2315773T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25
EP09781052.7A EP2315773B1 (en) 2008-07-25 2009-07-24 Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis

Publications (1)

Publication Number Publication Date
PL2315773T3 true PL2315773T3 (pl) 2017-07-31

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09781052T PL2315773T3 (pl) 2008-07-25 2009-07-24 Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy

Country Status (24)

Country Link
US (2) US20110117119A1 (pl)
EP (1) EP2315773B1 (pl)
JP (1) JP5873332B2 (pl)
KR (1) KR20110044883A (pl)
CN (1) CN102164952B (pl)
AU (1) AU2009273130B2 (pl)
BR (1) BRPI0916703A2 (pl)
CA (1) CA2731499C (pl)
CO (1) CO6341637A2 (pl)
CY (1) CY1118200T1 (pl)
DK (1) DK2315773T3 (pl)
EA (1) EA024826B1 (pl)
ES (1) ES2602430T3 (pl)
HR (1) HRP20161458T1 (pl)
HU (1) HUE031044T2 (pl)
IL (1) IL210559A0 (pl)
LT (1) LT2315773T (pl)
MX (1) MX2011000983A (pl)
PL (1) PL2315773T3 (pl)
PT (1) PT2315773T (pl)
SG (1) SG192456A1 (pl)
SI (1) SI2315773T1 (pl)
UA (1) UA107330C2 (pl)
WO (1) WO2010010177A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632646B1 (en) * 1998-11-04 2009-12-15 Isis Innovation Limited Tuberculosis diagnostic test
SG10201505149WA (en) * 2008-07-25 2015-07-30 Glaxosmithkline Biolog Sa Novel compositions and methods
CA2731547C (en) 2008-07-25 2019-04-30 Glaxo Group Limited The tuberculosis rv2386c protein, compositions and uses thereof
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
BRPI1006452A2 (pt) 2009-04-24 2016-12-27 Statens Seruminstitut vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo
EP2528621B1 (en) 2010-01-27 2016-09-21 GlaxoSmithKline Biologicals S.A. Modified tuberculosis antigens
ES2774965T3 (es) 2013-09-27 2020-07-23 Codexis Inc Modelado predictivo a base de estructura
ES2693150T3 (es) 2013-09-27 2018-12-07 Codexis, Inc. Filtración automática de variantes de enzimas
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
CA3142300A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US7087713B2 (en) * 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
CN1163602C (zh) * 1998-04-07 2004-08-25 科里克萨公司 结核杆菌抗原融合蛋白及其应用
DE60139963D1 (de) * 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
WO2002054072A2 (en) * 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
WO2002074903A2 (en) * 2001-02-22 2002-09-26 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP2226332A1 (en) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
NZ562729A (en) 2005-04-29 2009-10-30 Infectious Disease Res Inst Id Novel method for preventing or treating M tuberculosis infection using Mtb72f fusion proteins
EP1910409A2 (en) * 2005-06-23 2008-04-16 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
US9297803B2 (en) * 2006-11-01 2016-03-29 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
BRPI1006452A2 (pt) * 2009-04-24 2016-12-27 Statens Seruminstitut vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo
EP2528621B1 (en) 2010-01-27 2016-09-21 GlaxoSmithKline Biologicals S.A. Modified tuberculosis antigens

Also Published As

Publication number Publication date
CN102164952B (zh) 2016-05-25
EA024826B1 (ru) 2016-10-31
US9795663B2 (en) 2017-10-24
PT2315773T (pt) 2016-11-23
SI2315773T1 (sl) 2016-12-30
EP2315773B1 (en) 2016-08-24
CO6341637A2 (es) 2011-11-21
WO2010010177A1 (en) 2010-01-28
JP5873332B2 (ja) 2016-03-01
EP2315773A1 (en) 2011-05-04
CA2731499A1 (en) 2010-01-28
IL210559A0 (en) 2011-03-31
EA201100072A1 (ru) 2011-10-31
CY1118200T1 (el) 2017-06-28
SG192456A1 (en) 2013-08-30
LT2315773T (lt) 2016-11-10
CA2731499C (en) 2017-01-10
AU2009273130A1 (en) 2010-01-28
US20110117119A1 (en) 2011-05-19
US20140178423A1 (en) 2014-06-26
ES2602430T3 (es) 2017-02-21
DK2315773T3 (en) 2016-12-12
MX2011000983A (es) 2011-03-02
HRP20161458T1 (hr) 2016-12-16
BRPI0916703A2 (pt) 2019-12-24
JP2011528895A (ja) 2011-12-01
CN102164952A (zh) 2011-08-24
KR20110044883A (ko) 2011-05-02
HUE031044T2 (en) 2017-06-28
AU2009273130B2 (en) 2014-10-16
UA107330C2 (uk) 2014-12-25

Similar Documents

Publication Publication Date Title
SI2315773T1 (sl) Polipeptidi, polinukleotidi in sestavki za uporabo pri zdravljenju latentne tuberkuloze
AP2965A (en) Therapeutic compositions and the use thereof
AP2490A (en) Therapeutic compositions and the use thereof
PL1975226T3 (pl) Płynna kompozycja do obróbki
EP2314278A4 (en) HAIR TREATMENT COMPOSITION
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
IL207096A0 (en) Modified leptin polypeptides and their uses
IL195152A (en) Compounds for use in treating diseases of cell culture
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
IL215592A (en) Compounds, preparations containing them and their uses in the treatment or prevention of conditions in the eyes
PL2190405T3 (pl) Kompozycje do traktowania włosów
EP2172524A4 (en) RESIN COMPOSITION AND USE THEREOF
EP2209458A4 (en) SKIN TREATMENT COMPOSITIONS
PL2066408T3 (pl) Kompozycja na bazie ksantoksyliny i jej zastosowanie w kosmetyce
GB0719202D0 (en) Compositions and methods for the skin and hair
MX303262B (es) Composicion de locion para uso personal.
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
GB0822486D0 (en) Compounds for use in the treatment of pain
GB0714500D0 (en) composition and treatment
GB2461611B (en) Composition and use thereof
ZA200807154B (en) Liquid treatment composition
ZA201000469B (en) Therapeutic compositions and the use thereof
GB0622040D0 (en) Skin treatment composition
HK1172547A1 (en) Activin-actrii antagonists for use in treating anemia -actrii
GB0808877D0 (en) Composition and use thereof